Htlv-i tax induced killing of p53 null cancer cells
CA 2486327 A1 · Owner: University Of Virginia Patent Foundation · Inventors: Kupfer, Gary Michael; Semmes, Oliver John, Iv
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is based on the finding that expression of an exogenous nucleic acid encoding a polypeptide having human T-cell leukemia virus type I (HTLV-1) Tax activity in p53 cells results in a sensitization of those cells to DNA damaging agents. Therefore, the present invention is directed to a method of inducing cell death in p53 cells, enhancing susceptibility to such DNA damaging agents, and the selective cell killing of p53 cells. It has been found that retroviral vectors, and particularly lentiviral vectors are , suitable for the present invention to permit the transient expression of the HTLV-1 Tax protein in the p53 cells, which sensitizes the cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.